High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials

被引:1
|
作者
Shibasaki, Fumitaka [1 ]
Takeyama, Masahiro [2 ]
Ogiwara, Kenichi [2 ]
Furukawa, Shoko [2 ]
Nakajima, Yuto [2 ]
Shimonishi, Naruto [2 ]
Nogami, Keiji [2 ]
机构
[1] Nara Med Univ, Kashihara, Nara, Japan
[2] Nara Med Univ, Dept Pediat, 840 Shijo Cho, Kashihara, Nara 6348522, Japan
关键词
Acquired hemophilia A; Factor VIII; Anti-factor VIII antibody; Blood coagulation test; Factor VIII activity; VON-WILLEBRAND-FACTOR; HIGH PLASMA-LEVELS; THROMBIN GENERATION; VENOUS THROMBOEMBOLISM; 1ST REPORT; THROMBOMODULIN; RISK; ENDOTHELIUM; BINDING;
D O I
10.1007/s12185-022-03528-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Elevated factor VIII activity (FVIII:C) is often observed in patients with acquired hemophilia A (PwAHA) in remission. However, comprehensive coagulation potentials in this patient group remain to be investigated.Aim To evaluate comprehensive coagulation potentials in PwAHA.Methods We investigated coagulation function in eleven PwAHA with high FVIII:C (> 150 IU/dL) using thrombin generation assay (TGA) and/or rotational thromboelastometry (ROTEM), and compared findings with results obtained from contrived samples generated by spiking recombinant FVIII.Results The median FVIII:C and FVIII inhibitor titers during remission in enrolled PwAHA were 206 IU/dL and 0.44 BU/mL, respectively. In all patients, lag time and time to peak were either prolonged or normal compared to contrived samples corresponding to their FVIII:C. However, higher values of peak thrombin and endogenous thrombin potentials compared to contrived samples were observed in two patients. ROTEM parameters were within normal ranges in all cases. One patient (FVIII:C 171 IU/dL) developed venous thrombosis and pulmonary embolism, but TGA parameters showed low or normal coagulation potential compared to contrived samples corresponding to his FVIII:C.Conclusion PwAHA with high FVIII:C could exhibit lower coagulation potentials than those corresponding to their FVIII:C.
引用
收藏
页码:669 / 677
页数:9
相关论文
共 50 条
  • [41] High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII
    Miskiewicz, P.
    Milczarek-Banach, J.
    Rutkowska-Hinc, B.
    Kondracka, A.
    Bednarczuk, T.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (02) : 217 - 225
  • [42] Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
    Hatayama, Yuki
    Motokura, Toru
    Hosoda, Yuzuru
    Suzuki, Sayaka
    Namba, Hiroya
    Kato, Konami
    Kojima, Nao
    Horie, Takuya
    Iwamoto, Takuya
    Yamashita, Noriko
    Ichikawa, Hitomi
    Fukuda, Tetsuya
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [43] Exon skipping partially restores factor VIII coagulant activity in patients with mild hemophilia A with exon 13 duplication
    Acquila, Maura
    Pasino, Mirella
    Lanza, Tiziana
    Molinari, Angelo Claudio
    Rosano, Camillo
    Bicocchi, Maria Patrizia
    HAEMATOLOGICA, 2005, 90 (07) : 997 - 999
  • [44] Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
    Hatayama, Yuki
    Motokura, Toru
    Hosoda, Yuzuru
    Suzuki, Sayaka
    Namba, Hiroya
    Kato, Konami
    Kojima, Nao
    Horie, Takuya
    Iwamoto, Takuya
    Yamashita, Noriko
    Ichikawa, Hitomi
    Fukuda, Tetsuya
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [45] Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
    Hatayama, Yuki
    Motokura, Toru
    Hosoda, Yuzuru
    Suzuki, Sayaka
    Namba, Hiroya
    Kato, Konami
    Kojima, Nao
    Horie, Takuya
    Iwamoto, Takuya
    Yamashita, Noriko
    Ichikawa, Hitomi
    Fukuda, Tetsuya
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [46] Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
    Collins, P. W.
    Blanchette, V. S.
    Fischer, K.
    Bjorkman, S.
    Oh, M.
    Fritsch, S.
    Schroth, P.
    Spotts, G.
    Astermark, J.
    Ewenstein, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) : 413 - 420
  • [47] A modified chromogenic assay for the measurement of very low levels of factor VIII activity (FVIII:C)
    Yatuv, R
    Dayan, I
    Baru, M
    HAEMOPHILIA, 2006, 12 (03) : 253 - 257
  • [48] Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile
    Martinelli, Nicola
    Girelli, Domenico
    Lunghi, Barbara
    Pinotti, Mirko
    Marchetti, Giovanna
    Malerba, Giovanni
    Pignatti, Pier Franco
    Corrocher, Roberto
    Olivieri, Oliviero
    Bernardi, Francesco
    BLOOD, 2010, 116 (25) : 5688 - 5697
  • [49] Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan
    Masahiro Ieko
    Kazumasa Ohmura
    Sumiyoshi Naito
    Mika Yoshida
    Makoto Saito
    Kazuki Kiyohara
    Shinri Miyazima
    Takahiro Maeta
    Akihiro Ohtsu
    Kenji Shimosegawa
    Nobuhiko Takahashi
    Akitada Ichinose
    International Journal of Hematology, 2022, 115 : 11 - 20
  • [50] Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan
    Ieko, Masahiro
    Ohmura, Kazumasa
    Naito, Sumiyoshi
    Yoshida, Mika
    Saito, Makoto
    Kiyohara, Kazuki
    Miyazima, Shinri
    Maeta, Takahiro
    Ohtsu, Akihiro
    Shimosegawa, Kenji
    Takahashi, Nobuhiko
    Ichinose, Akitada
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (01) : 11 - 20